American Journal of Cardiovascular Drugs

Scope & Guideline

Transforming Cardiovascular Care Through Research

Introduction

Immerse yourself in the scholarly insights of American Journal of Cardiovascular Drugs with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN1175-3277
PublisherADIS INT LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2001 to 2024
AbbreviationAM J CARDIOVASC DRUG / Am. J. Cardiovasc. Drugs
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND

Aims and Scopes

The American Journal of Cardiovascular Drugs focuses on advancing knowledge and understanding in the field of cardiovascular pharmacotherapy. It serves as a platform for the dissemination of research findings, clinical studies, and reviews that address critical issues in cardiovascular medicine.
  1. Pharmacotherapy for Cardiovascular Diseases:
    The journal primarily emphasizes studies related to pharmacological treatments for various cardiovascular conditions, including heart failure, myocardial infarction, and arrhythmias.
  2. Meta-analyses and Systematic Reviews:
    A significant portion of the publications includes meta-analyses and systematic reviews that synthesize existing research to provide comprehensive insights into treatment efficacy and safety.
  3. Real-World Evidence:
    The journal publishes studies utilizing real-world data to assess the effectiveness and safety of cardiovascular drugs in everyday clinical practice, highlighting the practical implications of therapeutic choices.
  4. Emerging Therapies and Novel Agents:
    Research on new and emerging pharmacological agents for cardiovascular conditions is a key focus, showcasing advancements in drug development and innovative treatment strategies.
  5. Guideline-Directed Therapy:
    The journal emphasizes the importance of guideline-directed medical therapy, discussing strategies to optimize treatment adherence and improve patient outcomes.
The American Journal of Cardiovascular Drugs is currently witnessing several emerging themes and trends that reflect the evolving landscape of cardiovascular pharmacotherapy. These trends indicate a growing interest in innovative treatments and patient-centered care.
  1. SGLT2 Inhibitors and GLP-1 Receptor Agonists:
    There is a marked increase in studies focusing on the cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists, particularly in patients with heart failure and diabetes, showcasing their role in cardio-protection.
  2. Real-World Data Analyses:
    An emerging trend is the utilization of real-world data analyses to evaluate treatment outcomes, adherence, and healthcare resource utilization, providing insights that complement randomized controlled trials.
  3. Pharmacogenomics and Personalized Medicine:
    Research into pharmacogenomics and its application in personalized medicine is gaining traction, highlighting the importance of tailoring cardiovascular therapies to individual patient characteristics.
  4. Novel Antithrombotic Strategies:
    There is a rising interest in novel antithrombotic strategies and combination therapies, particularly in the context of high-risk patients and those with complex comorbidities.
  5. Health Economics and Cost-Effectiveness:
    Increasingly, studies evaluating the cost-effectiveness of cardiovascular therapies are appearing, reflecting a growing emphasis on the economic implications of treatment choices in healthcare.

Declining or Waning

While the journal maintains a robust focus on various aspects of cardiovascular pharmacotherapy, certain themes appear to be declining in prominence over recent years. These waning scopes reflect shifts in research interests and clinical priorities.
  1. Traditional Anticoagulation Strategies:
    Research focusing on traditional anticoagulants, such as warfarin, is becoming less frequent as newer direct oral anticoagulants (DOACs) gain prominence in clinical practice.
  2. Long-term Outcomes of Older Medications:
    Studies examining the long-term outcomes of older medications such as digoxin and certain beta-blockers are declining, as the focus shifts toward newer agents with better efficacy and safety profiles.
  3. Single-Agent Therapies:
    There is a noticeable decrease in publications centered around single-agent therapies, as combination therapies and multifactorial approaches gain attention for their enhanced effectiveness.

Similar Journals

CURRENT CARDIOLOGY REVIEWS

Transforming Cardiology Through Comprehensive Reviews
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-403XFrequency: 4 issues/year

CURRENT CARDIOLOGY REVIEWS, an esteemed journal published by BENTHAM SCIENCE PUBL LTD, is a pivotal resource in the field of cardiology and cardiovascular medicine. With an ISSN of 1573-403X and E-ISSN of 1875-6557, this journal presents comprehensive reviews that contribute significantly to the advancement of scientific knowledge and clinical practices in cardiology. Operating with open access options, CURRENT CARDIOLOGY REVIEWS is dedicated to bridging the gap between research and practice, thereby encouraging interdisciplinary collaboration and knowledge sharing. The journal has been instrumental in disseminating high-impact findings, consistently maintaining a Q2 category ranking in both Cardiology and Cardiovascular Medicine, as well as within the miscellaneous categories of Medicine, highlighting its relevance and respect in the academic community. Researchers, practitioners, and students alike will find valuable insights into contemporary cardiovascular issues, practices, and innovations that promote better patient outcomes. Based in the United Arab Emirates, CURRENT CARDIOLOGY REVIEWS encourages global contributions and reflects the latest advancements up to the year 2024, solidifying its role as an essential publication for those engaged in the quest for excellence in cardiovascular health.

Journal of Cardiovascular Medicine

Elevating Standards in Cardiovascular Medicine
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1558-2027Frequency: 12 issues/year

Welcome to the Journal of Cardiovascular Medicine, a leading platform for the dissemination of high-quality research in the field of cardiology and cardiovascular medicine. Published by Lippincott Williams & Wilkins, this esteemed journal boasts an ISSN of 1558-2027 and an E-ISSN of 1558-2035, reflecting its commitment to accessible and innovative cardiovascular research. With a significant impact factor and ranked Q2 in both Cardiology and Cardiovascular Medicine as well as in Medicine (Miscellaneous) for 2023, the journal is recognized for its contributions to advancing knowledge and practice in this critical area of health. The journal disseminates original research, reviews, and clinical studies, aimed at clinicians, researchers, and healthcare professionals who are dedicated to improving cardiovascular health outcomes. With a continuous commitment to evolving research from 2006 to 2024, the journal is an essential resource for those looking to stay at the forefront of the latest discoveries and methodologies in cardiovascular medicine.

Research Reports in Clinical Cardiology

Exploring Innovations in Heart Health Research
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-8475Frequency: 1 issue/year

Research Reports in Clinical Cardiology is a premier open-access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of clinical cardiology. Since its inception in 2010, the journal has become an essential resource for researchers, practitioners, and students seeking the latest insights and developments in cardiovascular research. With its commitment to disseminating high-quality research, Research Reports in Clinical Cardiology continually explores crucial topics ranging from innovative therapeutic interventions to the epidemiology of heart diseases, attracting contributions from leading experts in the field. The journal's open-access model ensures that vital research findings are accessible to a global audience, fostering collaboration and the exchange of knowledge. By prioritizing impactful and rigorous studies, this journal plays a significant role in shaping contemporary cardiovascular medicine and providing essential resources for ongoing education in this vital area of healthcare.

World Journal of Cardiology

Fostering collaboration and discovery in cardiovascular research.
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 1949-8462Frequency: 12 issues/year

World Journal of Cardiology, published by BAISHIDENG PUBLISHING GROUP INC, stands out as a pivotal resource in the field of cardiology and cardiovascular medicine. With an ISSN of 1949-8462, this journal serves a global audience, promoting knowledge dissemination and collaboration among researchers, healthcare professionals, and students dedicated to advancing cardiovascular health. The journal demonstrates its credibility and impact in the field by achieving a respectable Q2 ranking in the 2023 category of Cardiology and Cardiovascular Medicine. Notably, it is listed in the Scopus database, ranking #189 out of 387 journals, placing it in the 51st percentile, which underscores its relevance and contribution to contemporary cardiovascular research. Although it operates under a subscription model, the journal provides diverse access options, ensuring that critical findings reach a wide audience. Through its comprehensive scope and commitment to publishing high-quality articles, the World Journal of Cardiology plays a vital role in shaping the future of cardiovascular science, making it an invaluable asset for those involved in this essential discipline.

Journal fur Kardiologie

Transforming Cardiology Through Rigorous Research.
Publisher: KRAUSE & PACHERNEGG GMBHISSN: 1024-0098Frequency: 12 issues/year

The Journal fur Kardiologie, published by KRAUSE & PACHERNEGG GMBH, is a pivotal resource in the field of Cardiology and Cardiovascular Medicine. With an ISSN of 1024-0098 and an E-ISSN of 1680-936X, this journal has played a significant role in disseminating valuable research and clinical studies from 1998 until its coverage discontinuation in Scopus in 2017. Despite its Scopus rank being relatively low at #316/324 in its category, it continues to serve as a platform for emerging cardiology research. The journal’s scope encompasses various aspects of cardiovascular health, providing insights that are crucial for researchers, professionals, and students alike seeking to advance their knowledge and practice in cardiology. While the journal is not open access, its contributions to the field are essential for those looking to stay informed about the latest developments in cardiovascular medicine.

CARDIOVASCULAR DRUGS AND THERAPY

Elevating standards in cardiovascular drug therapy.
Publisher: SPRINGERISSN: 0920-3206Frequency: 6 issues/year

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Pioneering advancements in cardiovascular therapeutics.
Publisher: SAGE PUBLICATIONS INCISSN: 1074-2484Frequency: 6 issues/year

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

KARDIOLOGIYA

Cultivating a Legacy of Cardiac Research
Publisher: RUSSIAN HEART FAILURE SOCISSN: 0022-9040Frequency: 12 issues/year

KARDIOLOGIYA is a renowned academic journal in the field of cardiology, published by the Russian Heart Failure Society. Since its inception in 1961, this journal has been dedicated to disseminating cutting-edge research in cardiovascular medicine, contributing to the global understanding of heart-related diseases and their management. With a significant publication history that spans over six decades, KARDIOLOGIYA provides a platform for both established researchers and emerging scholars to publish their findings. Despite its current Q4 category ranking in the 2023 Cardiology and Cardiovascular Medicine category, the journal plays a crucial role in promoting regional insights and advancements in cardiology, while striving towards higher visibility and impact within the academic community. While not an open-access journal, the journal is accessible to institutions and professionals in the Russian Federation and beyond, fostering collaboration and knowledge sharing among healthcare professionals. With a Scopus rank of #259 among 387 journals, it is well-positioned to enhance discourse in the field and support the development of innovative approaches to cardiovascular care.

Journal of Cardiology

Driving breakthroughs in heart health and patient care.
Publisher: ELSEVIERISSN: 0914-5087Frequency: 12 issues/year

Journal of Cardiology, published by ELSEVIER, stands as a prominent resource in the field of cardiology and cardiovascular medicine. With a rich history since its inception in 1987, this peer-reviewed journal aims to disseminate cutting-edge research that enhances the understanding and treatment of cardiovascular diseases. Its 2023 ranking places it in the Q2 category within its discipline, reflecting its significance and impact, as evidenced by a Scopus rank of #123 out of 387 journals, positioning it in the 68th percentile of its field. The journal is headquartered in Japan, providing a unique perspective on cardiological advances relevant not only to the Asian continent but also globally. Though it does not currently offer open access, the Journal of Cardiology remains a vital institutional resource for researchers, clinicians, and students seeking to push the boundaries of cardiovascular science and improve patient outcomes.

Current Treatment Options in Cardiovascular Medicine

Elevating patient care through informed treatment strategies.
Publisher: SPRINGERNATUREISSN: 1092-8464Frequency: 12 issues/year

Current Treatment Options in Cardiovascular Medicine is a leading journal dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by SpringerNature, this journal seeks to bridge the gap between clinical practice and research by providing comprehensive reviews, insightful analyses, and updates on the latest treatment modalities available for cardiovascular diseases. With an ISSN of 1092-8464 and an E-ISSN of 1534-3189, it displays a commitment to disseminating critical information to healthcare professionals and researchers globally. Despite its recent categorization in the Q3 quartile, the journal continues to maintain relevance with a Scopus rank of #246 in the field, reflecting its contribution to the ongoing discourse in cardiovascular care. The publication encompasses a broad spectrum of topics, from interventional cardiology to pharmacotherapy, supporting the journal's objective to enhance patient care through evidence-based treatment options. Researchers, professionals, and students will find Current Treatment Options in Cardiovascular Medicine an indispensable resource for staying at the forefront of cardiovascular innovations and applications.